Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 597

1.
2.
3.

Impact of malnutrition and social determinants on survival of HIV-infected adults starting antiretroviral therapy in resource-limited settings.

Argemi X, Dara S, You S, Mattei JF, Courpotin C, Simon B, Hansmann Y, Christmann D, Lefebvre N.

AIDS. 2012 Jun 1;26(9):1161-6. doi: 10.1097/QAD.0b013e328353f363.

PMID:
22472856
4.

Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.

Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G; Italian MASTER Cohort.

Antivir Ther. 2007;12(6):941-7.

PMID:
17926648
5.

A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.

Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, Viard JP, Gatell J, Blaxhult A, Lundgren JD.

J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):369-78.

PMID:
10634199
6.

Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.

Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.

HIV Med. 2007 Jan;8(1):46-54.

7.

Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution.

Arici C, Ripamonti D, Ravasio V, Maggiolo F, Rizzi M, Finazzi MG, Suter F.

Int J STD AIDS. 2001 Sep;12(9):573-81.

PMID:
11516366
8.

CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.

McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.

Clin Infect Dis. 2005 Dec 1;41(11):1662-70. Epub 2005 Oct 19.

9.

Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).

Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J; PISCIS Study Group.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20.

PMID:
18297762
10.

Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.

Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P; Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA).

HIV Med. 2005 May;6(3):198-205.

11.

[Survival and immune response of rural HIV/AIDS patients after free antiretroviral therapy].

Ding YY, Jia WQ, Wang JS, Dong SL, Yang QH, Zhou RY, Qu SX, Lu LX, Wei J, Qiao XC, Gao MY, Guo XL, Zhang TJ, Wu ZY, He N.

Zhonghua Liu Xing Bing Xue Za Zhi. 2008 Dec;29(12):1176-80. Chinese.

PMID:
19173958
12.

Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania.

Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE, Gundersen SG, Bruun JN.

BMC Infect Dis. 2008 Apr 22;8:52. doi: 10.1186/1471-2334-8-52.

13.

Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.

Etard JF, Ndiaye I, Thierry-Mieg M, Guèye NF, Guèye PM, Lanièce I, Dieng AB, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E.

AIDS. 2006 May 12;20(8):1181-9.

PMID:
16691070
15.

Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study.

Berhane K, Karim R, Cohen MH, Masri-Lavine L, Young M, Anastos K, Augenbraun M, Watts DH, Levine AM.

J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1245-52.

PMID:
15385731
16.

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.

J Infect Dis. 2004 Sep 15;190(6):1046-54. Epub 2004 Aug 17.

17.

Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.

Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M; Swiss HIV Cohort Study.

Clin Infect Dis. 2005 Aug 1;41(3):361-72. Epub 2005 Jun 24.

18.

Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.

Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, Moeung S, Song S, Balkan S, Ferradini L, Quillet C, Fontanet A.

AIDS. 2007 Jan 30;21(3):351-9.

PMID:
17255742
19.

Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.

Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson JO, Bernasconi E, Terziroli B, Moirandat-Rytz S, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher HC, Battegay M, Koller MT; Swiss HIV Cohort Study.

Antivir Ther. 2007;12(6):931-9.

PMID:
17926647
20.

Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.

Diabaté S, Alary M.

HIV Med. 2009 Nov;10(10):640-6. doi: 10.1111/j.1468-1293.2009.00736.x. Epub 2009 Jul 29.

Items per page

Supplemental Content

Write to the Help Desk